Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china

References

• Rawla P, Sunkara T, Gaduputi V, Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol, 2019. 10(1): 10.
   PubMedGoogle Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): 394–424.
   PubMed Web of Science ®Google Scholar
• Zhang S, Huang X, Tian Y, et al. Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients in China. PeerJ, 2018. 6: e4893.
   PubMed Web of Science ®Google Scholar
• Zheng R, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi, 2019. 41(1): 19–28.
   PubMedGoogle Scholar
• Luo J, Xiao L, Wu C, et al. The incidence and survival rate of population-based pancreatic cancer patients: shanghai Cancer Registry 2004–2009. PloS One, 2013. 8(10):e76052.
   Web of Science ®Google Scholar
• De La Cruz MSD, Young AP, Ruffin MT, Diagnosis and management of pancreatic cancer. Am Fam Physician, 2014. 89(8): 626–632.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A, Cancer statistics, 2020. CA Cancer J Clin, 2020. 70(1): 7–30.
   PubMed Web of Science ®Google Scholar
• Scott E, Jewell A, Supportive care needs of people with pancreatic cancer: a literature review. Cancer Nurs Pract, 2019.18:35–43.
   Google Scholar
• National Health Commission of the People Republic of China, Chinese guidelines for diagnosis and treatment of pancreatic cancer 2018 (English version). Chin J Cancer Res, 2019. 31(2): p. 278
   PubMed Web of Science ®Google Scholar
• Zhi-min J, De-rong X, Xiao-rong L, Real-world comparative effectiveness of Nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer. J Evid Based Med, 2019. 19: 264–266.
   Google Scholar
• Liu GG, Vortherms SA, Hong X, China’s health reform update. Annu Rev Public Health, 2017. 38(1): 431–448.
   Web of Science ®Google Scholar
• Zhou J, Zhao R, Wen F, et al., Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. Tumori J, 2016. 102(3): 294–300
   Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011. 364(19): 1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med, 2013. 369(18): 1691–1703.
   PubMed Web of Science ®Google Scholar
• Kang J, Hwang I, Yoo C, et al., Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Invest New Drugs, 2018. 36(4): 732–741.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sanders GD, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 2016.
   Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. New York: Oxford University Press; 2015.
   Google Scholar
• Sonnenberg FA, Beck JR, Markov models in medical decision making: a practical guide. Med Decis Mak, 1993. 13(4): 322–338.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol, 2012. 12(1): 9.
   PubMed Web of Science ®Google Scholar
• Tang S, Chen W, Pharmacoeconomic study on 3 chemotherapy regimens for advanced pancreatic cancer in China based on Markov model. China Pharm, 2018. 29(6): 784–789.
   Google Scholar
• Zhou J, Zhao R, Wen F, et al. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Med Oncol, 2015. 32(4): 121.
   PubMed Web of Science ®Google Scholar
• Liu M, Qu S, Liu Y, et al. Comparative clinical effects and cost–effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China. J Comp Eff Res, 2019. 8(11): 865–877.
   PubMed Web of Science ®Google Scholar
• Sunshine Medical Procurement All-in-one. National centralized drug procurement list. [cited 2020 Jun 30]. Available from: http://www.smpaa.cn/gjsdcg/2020/01/21/9270.shtml
   Google Scholar
• IQVIA China. IQVIA China hospital pharmaceutical audit. Shanghai: IQVIA Inc; 2020.
   Google Scholar
• Committee of Chinese Society of Clinical Oncology guidelines, Guidelines of chinese society of clinical oncology (CSCO)-pancreatic cancer. 2019, Beijing: People’s Medical Publishing House.
   Google Scholar
• Qian Y, Zheng S, Efficacy and safety of modified FOLFIRINOX regimen in advanced pancreatic cancer: A multicenter prospective clinical study. Chin Clin Oncol, 2018;11:12.
   Google Scholar
• National Bureau of Statistics of China. The exchange rate between RMB and USD. 2019 [cited 2020 Jun 29]. Available from: http://data.stats.gov.cn/
   Google Scholar
• Attard C, Brown S, Alloul K, et al. Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. Current Oncol, 2014. 21(1): e41.
   PubMed Web of Science ®Google Scholar
• Gray AM, Clarke PM, Wolstenholme JL, et al. Applied methods of cost-effectiveness analysis in healthcare. New York: Oxford University Press; Vol. 3. 2011.
   Google Scholar
• Drummond MF, McGuire A, Handling uncertainty in economic evaluation and presenting the results, in Economic evaluation in health care: merging theory with practice. Drummond MF, McGuire A, editors. Oxford University Press, USA; 2001. p. 172–214.
   Google Scholar
• Briggs AH, Claxton K, Sculpher MJ Decision modelling for health economic evaluation. USA; Oxford University Press; 2006.
   Google Scholar
• Fenwick E, Claxton K, Sculpher M, Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ, 2001. 10(8): 779–787
   PubMed Web of Science ®Google Scholar
• European Network for Health Technology Assessment. Comparators & comparisons: direct and indirect comparisons.Copenhagen: EUnetHTA; 2013.
   Google Scholar
• Gharaibeh M, McBride A, Bootman JL, et al. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. J Med Econ, 2017. 20(4): 345–352.
   PubMed Web of Science ®Google Scholar